1stOncology™: Cancer Intelligence Service – Page 1085 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

TuHURA Biosciences Announces Participation in Upcoming Investor Conferences

On February 24, 2026 TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, reported that Dr. James Bianco, President and Chief Executive Officer, will participate in the following upcoming investor conferences:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Citizens Life Science Conference
Date: Tuesday, March 10, 2026
Time: 4:00 pm ET
Links: To register and view presentation, click HERE. A live and archived webcast of the presentation will also be available through the investors page of TuHURA’s corporate website at View Source

Leerink Global Healthcare Conference
Date: Wednesday, March 11, 2026
Time: TuHURA will be available to meet 1×1 with investors
Links: To request a meeting, please contact your Leerink representative

(Press release, TuHURA Biosciences, FEB 24, 2026, View Source [SID1234662939])

Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)

On February 24, 2026 Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies, reported that it has entered into a clinical collaboration agreement with Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", SEHK: 1877.HK; SSE: 688180). Under the collaboration, the parties will jointly evaluate the synergistic therapeutic potential of Antengene’s ATG-037, an oral small-molecule CD73 inhibitor, in combination with Junshi Biosciences’ JS207, a recombinant humanized anti-PD-1/VEGF bispecific antibody, in patients with solid tumors in Mainland China, with the goal of identifying clinical signals across multiple tumor types.

This collaboration builds on the encouraging Phase I proof-of-concept clinical data generated with ATG-037. At a time when resistance to checkpoint inhibitors (CPIs) has become a major clinical challenge, the Phase I study evaluating ATG-037 in combination with CPIs has already demonstrated promising potency into reversing CPI resistance. Beyond validating the synergistic potential of these two innovative drugs, this collaboration aims to advance the efficacy of existing immunotherapies and extend the overall survival (OS) of cancer patients through a "triple-axis" approach that incorporates immune checkpoint signalling, anti-angiogenesis, and the alleviation of adenosine-mediated immunosuppression.

ATG-037, Antengene’s orally administered small-molecule CD73 inhibitor, offers significant advantages over anti-CD73 monoclonal antibodies. In preclinical studies, ATG-037 demonstrated stronger inhibition of cell-surface CD73 enzymatic activity and overcame the "hook effect" commonly observed with antibody-based approaches. In addition, ATG-037’s higher tissue penetration compared with antibodies may facilitate complete CD73 inhibition at the cellular level. ATG-037 has demonstrated encouraging clinical activity in combination with anti–PD-1 therapy in patients with CPI-resistant melanoma and non-small cell lung cancer (NSCLC), based on the latest data presented at Antengene’s R&D Day in November 2025. In the ongoing Phase I/Ib STAMINA-01 study, the combination achieved an objective response rate (ORR) of 33.3% with a disease control rate (DCR) of 100% in patients with CPI-resistant melanoma, and an ORR of 21.4% with a DCR of 71.4% in patients with CPI-resistant NSCLC. The dataset was generated in Australia in patients with CPI-refractory solid tumors, with pembrolizumab and/or nivolumab as the predominant prior anti–PD-1 therapies, and more than 70% of melanoma patients were refractory to both anti–PD-1 and anti–CTLA-4 (ipilimumab). These results support ATG-037’s clinically meaningful activity across multiple tumor types, particularly in patients with prior immunotherapy resistance. Importantly, ATG-037 has demonstrated a favorable safety and tolerability profile in combination treatment, with no new or unexpected safety signals observed, including in patients receiving long-term therapy. Grade 3 or higher treatment-related adverse events only occurred in 7.9% of patients. Responses have also shown encouraging durability, including a patient who achieved a complete response and has remained on study for over three years and is currently receiving ATG-037 monotherapy for more than a year, as well as multiple patients with durations of response exceeding 12 months. These data support ATG-037’s potential role as a backbone agent for next-generation immuno-oncology combination regimens.

JS207, Junshi Biosciences’ independently developed recombinant humanized anti-PD-1/VEGF bispecific antibody, has demonstrated promising anti-tumor activity and a manageable safety profile in both preclinical and clinical studies. JS207’s preclinical studies demonstrated its robust anti-tumor efficacy in multiple tumor models and supported a differentiated mechanism of action, with VEGFA shown to enhance JS207’s antigen binding activity, T-cell activation potency and internalization of cell-surface PD-1. In a poster presented at ESMO (Free ESMO Whitepaper) Asia 2025, JS207 monotherapy showed encouraging efficacy across solid tumors. 62 patients with PD-L1 positive NSCLC received JS207 monotherapy as first-line treatment, and achieved an ORR of 58.1% and a DCR of 87.1%. Clinical activity has also been observed in additional tumor types, including hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC), supporting the potential of PD-1/VEGF dual targeting across multiple tumor settings. To date, JS207 has 11 ongoing phase II clinical studies, exploring its use in combination with chemotherapy, monoclonal antibodies, antibody-drug conjugates (ADCs) and other drugs in NSCLC, colorectal cancer, triple-negative breast cancer, liver cancer and other tumor types, with nearly 500 patients enrolled. Based on the accumulated data from these studies, the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application, allowing Junshi Biosciences to initiate an open-label, two-arm, randomized, active-controlled, Phase II/III clinical study comparing JS207 to nivolumab for the neoadjuvant treatment of patients with stage II/III, resectable, actionable genomic aberration (AGA)-negative NSCLC.

The scientific rationale for the collaboration is based on the complementary and potentially synergistic mechanisms of CD73 inhibition and dual PD-1/VEGF targeting. CD73 is recognized as a key regulator of immune suppression and angiogenesis within the tumor microenvironment through the generation of adenosine, which can dampen anti-tumor immune responses. In both clinical and preclinical settings, CD73 inhibitors have demonstrated meaningful synergy with anti–PD-1 monoclonal antibodies. In addition, CD73 activity has been shown to promote angiogenesis, including through upregulation of VEGF signaling, and may contribute to the development of resistance to anti-VEGF therapies. Given the broad relevance of immune suppression, angiogenesis and adenosine signaling across solid tumors, this combination strategy has the potential to be applicable across multiple tumor types. Taken together, these observations suggest that combining CD73 blockade with PD-1/VEGF-directed approaches has the potential to enhance and sustain therapeutic effects. Together, the combination of ATG-037 with JS207 represents a potential "triple-axis" approach that simultaneously modulates immune checkpoint signaling, angiogenesis, and the adenosine pathway. With the potential to deepen responses while maintaining a favorable safety profile, the combination of ATG-037 with JS207 may further improve the durability of benefit and may translate into improved OS.

We look forward to working closely with Junshi Biosciences and leveraging our respective expertise in target biology and clinical development to accelerate the evaluation of ATG-037 in combination with JS207 across multiple solid tumor types, with the goal of identifying clinical signals and delivering more innovative treatment options for patients in Mainland China.

(Press release, Antengene, FEB 24, 2026, View Source [SID1234662938])

Krystal Biotech to Present at TD Cowen 46th Annual Health Care Conference

On February 24, 2026 Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS) reported that the Company will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026, in Boston. Company executives will take part in a fireside chat scheduled at 3:10 pm ET and host investor meetings throughout the day.

A webcast of the presentation will be available here beginning at 3:10 pm ET on Tuesday, March 3, 2026 and will be posted on the Investors section of the Company’s website.

(Press release, OmniAb, FEB 24, 2026, View Source [SID1234662937])

OmniAb to Participate at the Leerink Partners Global Healthcare Conference

On February 24, 2026 OmniAb, Inc. (NASDAQ: OABI) reported that management will participate at the Leerink Global Healthcare Conference taking place March 8-11, 2026, at the W South Beach in Miami. Management will present a corporate overview on Tuesday, March 10th at 3:40 p.m. Eastern time and will hold one-on-one meetings with investors registered for the event.

Investors interested in scheduling a meeting with OmniAb management should contact their Leerink Partners representative, or email [email protected].

(Press release, OmniAb, FEB 24, 2026, View Source [SID1234662936])

Sandoz delivers strong full-year results; guidance for 2026 reflects an expected acceleration in growth

On February 24, 2026 Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in affordable medicines, reported its financial results for the full year and net sales for the fourth quarter of 2025.

FINANCIAL RESULTS

FY 2025

FY 2024

change

USD m

USD %

CC %1,2

CGR %3

Net sales

11,086

10,357

Generics

7,794

7,504

Biosimilars

3,292

2,853

15%

13%

18%

Core EBITDA

2,405

2,080

16%

14%

Core EBITDA margin

21.7%

20.1%

Core diluted earnings per share

USD 3.64

USD 2.71

34%

33%

Management free cash flow

1,547

1,112

39%

Core return on invested capital

14.5%

12.3%

Richard Saynor, Chief Executive Officer of Sandoz, said: "Our strong financial results in 2025 demonstrate the excellent headway we’re making. It was a year marked by the progress of our industry-leading pipeline, a record number of launches and significant investment in securing our biosimilars leadership for years to come. Our unrelenting focus on top-line growth, profitability and cash generation positions Sandoz well to deliver even more for patients and shareholders.

"We will build on this momentum in 2026. Alongside our launch program, we plan to extend patient access, expand the pipeline and make further efficiency gains. As we cement our leadership in affordable medicines, we have an excellent platform to meet the unprecedented opportunities ahead and deliver strong results in a high-growth, attractive market."

1 Constant currencies.

2 Non-IFRS measures are defined in the Supplementary financial information section of the Integrated Annual Report 2025.

3 Sandoz defines the comparable growth rate (CGR) as the growth rate of net sales at CC excluding the effects of material acquisitions and divestments. In the case of divestments, net sales are excluded for the corresponding period. Similarly, for acquisitions, the relevant net sales are excluded for the corresponding period. Material acquisitions and divestments are transactions in scope of significant transactions in the Company’s consolidated financial statements. Sandoz believes the presentation of CGR is meaningful for management and investors to evaluate the performance of the business over time.

FINANCIAL HIGHLIGHTS

FY 2025 net sales of USD 11.1 billion
Up by 5% at CC and 7% in USD in the year, with volume growth of 8%; on a CGR basis, net sales grew by 6%
Biosimilar sales up by 13% at CC in the year and by 18% at CGR; generics growth of 2% at CC and CGR
The biosimilar share of total net sales increased to 30% (FY 2024: 28%)
The 10 largest-selling medicines grew by a combined 10% at CC in the year and represented 33% of net sales
In the fourth quarter, net sales of USD 3.0 billion represented growth of 6% at CC and 12% in USD; on a CGR basis, net sales grew by 7% in the quarter
Core EBITDA-margin expansion in FY 2025 of 160 basis points to 21.7%, driven by a favorable mix of sales, operational efficiencies and cost discipline
Core diluted earnings per share in the year up by 33% at CC to USD 3.64, mainly benefitting from growth in core net income
Management free cash flow, defined as free cash flow adjusted for one-off items, amounted to
USD 1.5 billion (FY 2024: USD 1.1 billion), with the increase primarily driven by the growth in core EBITDA
A core return on invested capital (ROIC) of 14.5% in FY 2025 (FY 2024: 12.3%), principally a result of the strong growth in core operating income
A proposed dividend per share of CHF 0.804 (FY 2024: CHF 0.60), representing 27% of core net income
Full-year 2026 guidance of mid-to-high single-digit net-sales growth5 and core EBITDA-margin expansion of around 100 basis points

BUSINESS HIGHLIGHTS

2025 was a milestone year for Sandoz, marked by a wave of launches across biosimilars and generics, significant progress on the transformation journey and strong financial results. The biosimilars business continued to perform strongly, supported by major launches:

Pyzchiva (ustekinumab) was launched in the US in February 2025, offering new treatment options for around 12 million patients with chronic inflammatory diseases such as psoriasis and psoriatic arthritis. The rollout included a full suite of dosing options and extended stability compared to the reference medicine
The Pyzchiva autoinjector was launched in Europe in May 2025, the first ustekinumab biosimilar in Europe available in a pre-filled pen, with an improved self-administration experience supporting better treatment adherence and quality of life
Wyost & Jubbonti (denosumab) were launched in the US in June 2025 as the first FDA6-approved interchangeable denosumab biosimilars, providing affordable treatment options for osteoporosis and cancer-related skeletal events, cementing Sandoz’s leadership in oncology and immunology biosimilars
Tyruko (natalizumab) was launched in the US in November 2025 as the first and only multiple-sclerosis biosimilar, approved for all indications of the reference medicine
Afqlir (aflibercept) was launched in Europe in November 2025, offering an affordable-treatment option for retinal diseases such as neovascular age-related macular degeneration, expanding Sandoz’s presence in the ~USD 15 billion anti-VEGF7 market
Wyost & Jubbonti were launched in Europe in December 2025

In November 2025, Sandoz signed a global license agreement with EirGenix Inc. to commercialize a proposed biosimilar of pertuzumab for HER2‑positive early and metastatic breast cancer, a market worth approximately USD 4.1 billion8, strengthening the Company’s oncology portfolio and complementing its trastuzumab biosimilars.

In December 2025, Sandoz completed the strategic acquisition of Just-Evotec Biologics EU SAS, including a site in Toulouse, France, expanding in-house development and manufacturing capabilities. In addition, Sandoz acquired an indefinite license to Just-Evotec Biologics, Inc.’s cutting-edge continuous-manufacturing technology. These acquisitions complemented ongoing investments in Slovenia, as Sandoz builds a vertically integrated European biosimilar development and manufacturing network.

In 2025, Sandoz increased the availability of affordable medicines through several important generic launches, including rivaroxaban in Germany, expanding access to high-quality antithrombotic treatment options with multiple dosage forms. In September 2025, Sandoz launched its iron-sucrose injection in the US, broadening access to affordable treatment for iron-deficiency anemia in patients with chronic kidney disease and complementing its injectable iron-therapy portfolio.

The Sandoz pipeline is industry‑leading, with 27 biosimilar assets and around 400 generics in development, targeting around USD 420 billion in originator sales. In 2025, the pipeline benefited from positive shifts in regulatory streamlining across key biosimilar programs – developments that are expected to deliver meaningful advantages for both patients and Sandoz.

4 Subject to approval at the Annual General Meeting on April 9, 2026.

5 At CC.

6 US Food & Drug Administration.

7 Vascular endothelial growth factor.

8 Evaluate Pharma, Summary: worldwide sales (last accessed November 2025).

FULL-YEAR 2026 GUIDANCE

Sandoz anticipates an acceleration of net-sales growth in 2026, partly reflecting the expected performance of recently launched biosimilars. This growth, alongside a favorable movement in the mix of sales, further operating efficiencies and cost discipline, is expected to result in expansion in the core EBITDA margin.

As a result, the Company provides its financial guidance for 2026:

Net sales to grow at CC by a mid to high single-digit percentage
Core EBITDA-margin expansion of around 100 basis points

No material contribution from any potential launch of generic semaglutide is expected in 2026, while overall pricing is expected to decline by a low to mid single‑digit percentage. The guidance excludes any impacts of unforeseen events or unconfirmed developments, including the imposition of new tariffs emanating from the US government.

PENICILLINS: TRADE DISTORTION

As part of its vertically integrated penicillins production, the Company sells certain amounts of active pharmaceutical ingredients (APIs) to other businesses. The imposition of tariffs by the US government in 2025 led to reduced exports from China to the US, prompting Chinese suppliers to significantly lower global prices for key penicillin APIs, including 6‑Aminopenicillanic acid (6‑APA), the foundational compound for all penicillins. This price decline coincided with an increase in global market supply. These dynamics adversely impacted the Sandoz generics net-sales performance in H2 2025; a similar impact is expected in the first half of 2026. No imminent return to prior market conditions is anticipated.

The recently announced introduction of a minimum import price of 6‑APA in India is expected to curb the inflow of low‑priced imports, primarily from China, and support the domestic fermentation‑based antibiotic production in India. This risks a diversion of the supply of low-cost 6-APA towards Europe, which continues to depend on Asia for key intermediates.

CONFERENCE CALL

A conference call and webcast for investors and analysts will begin today at 9.30am CET. Details can be found here, with the accompanying presentation here.

(Press release, Sandoz, FEB 24, 2026, View Source [SID1234662935])